Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 13 (4) , 280-286
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Difficulty in predicting survival in metastatic renal cancerThe Lancet Oncology, 2012
- Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyThe Lancet Oncology, 2012
- Targeted therapeutic strategies for the management of renal cell carcinomaCurrent Opinion in Oncology, 2012
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working GroupClinical Cancer Research, 2011
- mTOR Inhibitors in Advanced Renal Cell CarcinomaHematology/Oncology Clinics of North America, 2011
- Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell CarcinomaDrugs, 2011
- Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical EvidenceThe Oncologist, 2011
- Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and TomorrowThe Oncologist, 2011
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Novel approaches in the therapy of metastatic renal cell carcinomaWorld Journal of Urology, 2005